GlassScriptPhysician profile
Mark R Mandel
NPI 1770541294
$4,565.44
in general payments reported to CMS, 2019-2025
22 companies · $618 in 2025
The $618 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $311 · 2021: $172 · 2022: $1,675 · 2023: $453 · 2024: $889 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,944 · Entertainment: $16.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,944.14 |
| Entertainment | $16.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,603.05 | 2019-2025 | Clareon, Unity, Hydrus Microstent |
| Glaukos Corporation | $1,075.41 | 2022-2025 | Ce-Marked Kxla System, Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Johnson & Johnson Surgical Vision, INC. | $535.79 | 2019-2025 | Tecnis Simplicity |
| Biotissue Holdings INC. | $280.34 | 2024-2025 | |
| Rxsight INC | $201.56 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Novartis Pharmaceuticals Corporation | $133.57 | 2019-2022 | |
| Allergan, INC. | $126.40 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $124.96 | 2019 | |
| Apellis Pharmaceuticals, INC. | $55.97 | 2024-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $47.63 | 2023 | Miebo |
| Carl Zeiss Meditec USA, INC. | $46.32 | 2022 | |
| Abbvie INC. | $42.51 | 2022 | |
| Dompe US, INC. | $42.35 | 2021-2025 | Oxervate |
| Shire North American Group INC | $41.27 | 2019 | |
| Ani Pharmaceuticals, INC. | $35.04 | 2024 | Purified Cortrophin Gel |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $34.17 | 2024 | Izervay |
| Harrow Eye, LLC | $33.84 | 2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $26.32 | 2022 | |
| Horizon Therapeutics Plc | $23.80 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $20.62 | 2021 | |
| Thea Pharma INC. | $18.38 | 2023 | |
| Optos, INC. | $16.14 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.